Differentiation of Low-Grade Oligodendrogliomas from Low-Grade Astrocytomas by Using Quantitative Blood-Volume Measurements Derived from Dynamic Susceptibility Contrast-Enhanced MR Imaging

References

1. ↵
   Lopes M, Laws EJ. Low-grade central nervous system tumors. Neurosurg Focus 2002;12:1–4

   PubMed
2. ↵
   Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma” J Neuropathol Exp Neurol 2002;61:58–63

   PubMedWeb of Science
3. ↵
   van den Bent M. New perspectives for the diagnosis and treatment of oligodendroglioma Expert Rev Anticancer Ther 2001;1:348–356

   CrossRefPubMed
4. ↵
   Pomper MG, Port JD. New techniques in MR imaging of brain tumors Magn Reson Imaging Clin N Am 2000;8:691–713

   PubMed
5. ↵
   Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings Radiology 1994;191:41–51

   PubMedWeb of Science
6. ↵
   Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging Radiology 1999;211:791–798

   CrossRefPubMedWeb of Science
7. ↵
   Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas AJR Am J Roentgenol 1998;171:1479–1486

   CrossRefPubMedWeb of Science
8. ↵
   Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas Clin Cancer Res 2000;6:2189–2200

   Abstract/FREE Full Text
9. ↵
   Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas AJNR Am J Neuroradiol 2004;25:214–221

   Abstract/FREE Full Text
10. ↵
    Kleihues P, Sobin LH. World Health Organization classification of tumors Cancer 2000;88:2887

    CrossRefPubMedWeb of Science
11. ↵
    Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas Cancer 1997;79:1381–1393

    CrossRefPubMedWeb of Science
12. ↵
    Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics Am J Physiol 1999;277:R1218–1229

    PubMedWeb of Science
13. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro-oncol 2000;2:45–59

    Abstract/FREE Full Text
14. ↵
    Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside J Neurooncol 2003;65:37–48

    CrossRefPubMed
15. ↵
    Prados MD, Levin V. Biology and treatment of malignant glioma Semin Oncol 2000;27:1–10

    PubMedWeb of Science
16. ↵
    Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion J Neurosurg 2001;94:978–984

    PubMed
17. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications Front Biosci 2000;5:D213–231

    PubMedWeb of Science
18. Fathallah-Shaykh HM, Zhao LJ, Mickey B, Kafrouni AI. Molecular advances to treat cancer of the brain Expert Opin Investig Drugs 2000;9:1207–1215

    PubMed
19. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 1998;90:1473–1479

    Abstract/FREE Full Text
20. ↵
    Bogler O, Huang HJ, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors Glia 1995;15:308–327

    CrossRefPubMedWeb of Science
21. ↵
    Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas J Clin Oncol 2000;18:636–645

    Abstract/FREE Full Text
22. ↵
    Mineura K, Shioya H, Kowada M, Ogawa T, Hatazawa J, Uemura K. Blood flow and metabolism of oligodendrogliomas: a positron emission tomography study with kinetic analysis of 18F-fluorodeoxyglucose J Neurooncol 1999;43:49–57

    CrossRefPubMed
23. ↵
    Christov C, Gherardi RK. Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis Acta Neuropathol (Berl) 1999;97:429–432

    CrossRefPubMed
24. ↵
    Varlet P, Guillamo JS, Nataf F, Koziak M, Beuvon F, Daumas-Duport C. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival Neuropathol Appl Neurobiol 2000;26:379–389

    CrossRefPubMedWeb of Science
25. ↵
    Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas Neuropathol Appl Neurobiol 1998;24:29–35

    CrossRefPubMedWeb of Science
26. ↵
    Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis Cancer 2001;92:165–171

    CrossRefPubMed
27. ↵
    Schiffer D, Bosone I, Dutto A, Di Vito N, Chio A. The prognostic role of vessel productive changes and vessel density in oligodendroglioma J Neurooncol 1999;44:99–107

    CrossRefPubMed
28. ↵
    Schiffer D, Dutto A, Cavalla P, et al. Prognostic factors in oligodendroglioma Can J Neurol Sci 1997;24:313–319

    PubMedWeb of Science
29. ↵
    Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE. Oligodendroglioma: histologic evaluation and prognosis J Neuropathol Exp Neurol 1986;45:65–78

    PubMedWeb of Science